Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 1/20 | 0.42 |
| ▸ | PLAT | P00750 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.41 |
| ▸ | NCF1 | P14598 | 1/20 | 0.40 |
| ▸ | TACR3 | P29371 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.35 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.35 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CPN1 | P15169 | 1/20 | 0.34 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2337249 | 1.00 | PLG (0.42) | PLGPLATLMNACHRM2CHRM1 | |
| SCHEMBL3155411 | 1.00 | PLG (0.42) | PLGPLATLMNACHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL25287438 | 0.98 | PLG (0.41) | PLGPLATLMNACHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL25248778 | 0.98 | PLG (0.41) | PLGPLATLMNACHRM2CHRM1 | |
| Tert-Butanol SCHEMBL28550813 | 0.91 | CHRM2 (0.43) | PLGPLATLMNACHRM2CHRM1 | |
| SCHEMBL1694214 | 0.88 | ITGB3 (0.43) | PLGPLATLMNACHRM2CHRM1 | |
| SCHEMBL1694358 | 0.88 | ITGB3 (0.43) | PLGPLATLMNACHRM2CHRM1 | |
| SCHEMBL856443 | 0.88 | ITGB3 (0.43) | PLGPLATLMNACHRM2CHRM1 | |
| SCHEMBL600521 | 0.87 | PLG (0.50) | PLGPLATLMNACHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL5249863 | 0.85 | PLG (0.48) | PLGPLATLMNACHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024105007-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF | Samsara Therapeutics Inc. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-11958833-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2024-04-16 | — | — | US | disclosed |
| WO-2023244917-A1 | 1,8-NAPHTHYRIDIN-2-ONE HETEROBIFUNCTIONAL BCL6 DEGRADERS | Treeline Biosciences, Inc. (US) | 2023-12-21 | — | — | WO | disclosed |
| EP-4257591-A2 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Celgene Quanticel Research, Inc. (US) | 2023-10-11 | — | — | EP | disclosed |
| US-20230150970-A1 | AMINOPYRIMIDINE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | DONG-A ST CO., LTD. (KR) | 2023-05-18 | — | — | US | disclosed |
| EP-4126839-A1 | AMINOPYRIMIDINE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | Dong-A ST Co., Ltd. (KR) | 2023-02-08 | — | — | EP | disclosed |
| EP-4122929-A1 | NOVEL COMPOUNDS | Mission Therapeutics Limited (GB) | 2023-01-25 | — | — | EP | disclosed |
| EP-3080100-B1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2022-11-30 | — | — | EP | disclosed |
| US-20220370431-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2022-11-24 | — | — | US | disclosed |
| US-11390604-B2 | Imidazole-pyrazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2022-07-19 | — | — | US | disclosed |
| US-20050043347-A1 | Thienopyridine and furopyridine kinase inhibitors | ABBVIE INC. | 2005-02-24 | — | — | US | disclosed |
| US-20050043325-A1 | Novel pharmaceuticals | PFIZER INC | 2005-02-24 | — | — | US | disclosed |
| WO-2005010009-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20050020619-A1 | Thienopyridine kinase inhibitors | ABBOTT LABORATORIES | 2005-01-27 | — | — | US | disclosed |
| WO-2004096810-A1 | 5,7-DIAMINOPYRAZOLO`4,3-D!PYRIMIDINES USEFUL IN THE TREATMENT OF HYPERTENSION | PFIZER LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |
| EP-1136477-B1 | BENZOFURAN DERIVATIVES, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2004-03-10 | — | — | EP | disclosed |
| US-20040034049-A1 | Promoters for the proliferation and differentiation of stem cells and/or neuron precursor cells | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-02-19 | — | — | US | disclosed |
| US-6479536-B1 | Benzofuran derivatives, process for the preparation of the same and uses thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-11-12 | — | — | US | disclosed |
| US-20020160996-A1 | Benzofuran derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2002-10-31 | — | — | US | disclosed |
| EP-1136477-A1 | BENZOFURAN DERIVATIVES, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2001-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220370431-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | MYC, MYCBP, MYCBP2 | PLG 4492/4885PLAT 4066/4885LMNA 1484/4885 |
| US-11390604-B2 | Imidazole-pyrazole derivatives | F12, CYP3A7, NLRP3 | PLG 3520/4885PLAT 3350/4885LMNA 3942/4885 |
| US-20050043325-A1 | Novel pharmaceuticals | ABCB11, PCSK9, SLC10A1 | PLG 2044/4885PLAT 1767/4885LMNA 4275/4885 |
| US-20050020619-A1 | Thienopyridine kinase inhibitors | ABL1, MAP4K2, MAP4K5 | PLG 3445/4885PLAT 1213/4885LMNA 4657/4885 |
| US-20050043347-A1 | Thienopyridine and furopyridine kinase inhibitors | ABL1, ERBB2, LCK | PLG 3686/4885PLAT 1123/4885LMNA 4652/4885 |
| US-20040034049-A1 | Promoters for the proliferation and differentiation of stem cells and/or neuron precursor cells | NES, HAT1, PROX1 | PLG 4759/4885PLAT 4755/4885LMNA 1890/4885 |
| US-20230150970-A1 | AMINOPYRIMIDINE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | AHR, ARNT, AIPL1 | PLG 4679/4885PLAT 3733/4885LMNA 4343/4885 |
| US-20020160996-A1 | Benzofuran derivatives, their production and use | PARK7, WDR1, WHR1 | PLG 4465/4885PLAT 4659/4885LMNA 972/4885 |
| US-11958833-B2 | Compounds | USP30, USP20, USP10 | PLG 3553/4885PLAT 4602/4885LMNA 2533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.